FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313703357> ?p ?o ?g. }

• W4313703357 endingPage "70" @default.
• W4313703357 startingPage "58" @default.
• W4313703357 abstract "To investigate the influence of sodium/glucose cotransporter-2 inhibitors (SGLT-2i) on renal function during the course of its administration, particularly in the initial weeks.Randomized controlled trials (RCTs) related to SGLT-2i were searched in databases (MEDLINE, EMBASE, and Cochrane Central Register) from the database's inception to August 31, 2021. All RCTs reported the kidney outcomes of SGLT2i versus active or placebo control were included, regardless of the presence of diabetes in the patients and the baseline estimated glomerular filtration rate (eGFR). The Cochrane Collaboration risk of bias tool was used to assess the quality of the included studies. All outcome comparisons were performed using the RevMan 5.4 software.Eleven RCTs with 58 534 participants reporting prespecified renal outcomes were identified. There was no heterogeneity in the baseline eGFR and urine albumin-to-creatinine ratio in the included studies. In the initial 2-4 weeks, there was an acute decline of eGFR in the SGLT-2i group compared with placebo group (weighted mean difference [WMD] -3.35 ml/min/1.73 m2 ; 95% CI, -3.81 to -2.90; I2 = 35%, p = .15); When compared to baseline eGFR in the SGLT-2i group, the WMD was -4.02 ml/min/1.73 m2 (95% confidence interval [CI], -3.61 to -4.44; I2 = 0%, p = .45). The renoprotective effect gradually appeared, and the decline rate of eGFR in the SGLT-2i group was sustained slower than placebo. However, the statistically significant benefit of SGLT-2i did not appear until the 104th week (the second year) (WMD 0.35 ml/min/1.73 m2 , 95% CI, 0.04 to 0.66; I2 = 45%, p = .08). Subgroup analysis showed SGLT-2i had a similar benefit on renal function regardless of baseline eGFR values.SGLT-2i consistently slowed the deterioration of eGFR since the early stage of administration, even in patients with chronic kidney disease. However, there was an acute decline in eGFR in the initial 2-4 weeks; afterwards the renoprotective effect of SGLT-2i gradually appeared and remained stable in the next few years.目的: 探讨SGLT-2抑制剂(SGLT-2i)在给药过程中, 特别是最初几周对肾功能的影响。 材料和方法: 从数据库创建至2021年8月31日, 在数据库(MEDLINE、EMBASE和Cochrane Central Register)中搜索与SGLT-2i相关的随机对照试验(RCTs)。所有纳入的RCT研究都报告了SGLT-2i组与安慰剂组的肾脏结局, 无论患者是否存在糖尿病和基线估算肾小球滤过率 (eGFR)。本研究采用Cochrane风险偏倚评估工具来评估纳入研究的质量。所有结果比较均使用RevMan 5.4软件进行。 结果: 共纳入11项RCT研究, 包含的58534名参与者报告了预先指定的肾脏结果。在纳入的研究中, 基线eGFR和UACR没有异质性。在最初的2-4周内, 与安慰剂组相比, SGLT-2i组eGFR快速下降( 加权均数差(WMD) -3.35ml/min/1.73m2 ; 95%CI,-3.81~-2.90; I2 =35%, P=0.15);与SGLT-2i组的基线eGFR相比, WMD为-4.02 ml/min/1.73m2 (95%CI, -3.61~-4.44; I2 =0%, P=0.45)。肾保护作用逐渐显现, SGLT-2i组eGFR下降速度持续慢于安慰剂组。然而, SGLT-2i直到第104周(第二年)才出现统计学上显著的益处(WMD 0.35ml/min/1.73m2 ,95%CI, 0.04~0.66; I2 =45%, P=0.08)。亚组分析显示, 无论eGFR基线值如何, SGLT-2i对肾功能具有相似的益处。 结论: SGLT-2i早期就能持续减缓eGFR的恶化, 即使在慢性肾病患者中也是如此。然而, 在最初的2-4周内, eGFR快速下降, 之后SGLT-2i的肾脏保护作用逐渐显现, 并在接下来的几年保持稳定。." @default.
• W4313703357 created "2023-01-08" @default.
• W4313703357 creator A5001830358 @default.
• W4313703357 creator A5056754675 @default.
• W4313703357 creator A5082538862 @default.
• W4313703357 creator A5086188167 @default.
• W4313703357 date "2023-01-01" @default.
• W4313703357 modified "2023-09-30" @default.
• W4313703357 title "Effect of sodium‐glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta‐analysis" @default.
• W4313703357 cites W1973038508 @default.
• W4313703357 cites W2026412750 @default.
• W4313703357 cites W2030311010 @default.
• W4313703357 cites W2098923148 @default.
• W4313703357 cites W2133169646 @default.
• W4313703357 cites W2141800817 @default.
• W4313703357 cites W2150219016 @default.
• W4313703357 cites W2152413054 @default.
• W4313703357 cites W2154020052 @default.
• W4313703357 cites W2424539745 @default.
• W4313703357 cites W2425017047 @default.
• W4313703357 cites W2492672367 @default.
• W4313703357 cites W2500767839 @default.
• W4313703357 cites W2554387255 @default.
• W4313703357 cites W2588681363 @default.
• W4313703357 cites W2614462090 @default.
• W4313703357 cites W2759467499 @default.
• W4313703357 cites W2793355388 @default.
• W4313703357 cites W2807732548 @default.
• W4313703357 cites W2808725516 @default.
• W4313703357 cites W2809703743 @default.
• W4313703357 cites W2890282628 @default.
• W4313703357 cites W2894993577 @default.
• W4313703357 cites W2939222610 @default.
• W4313703357 cites W2949665037 @default.
• W4313703357 cites W2965440006 @default.
• W4313703357 cites W2971414122 @default.
• W4313703357 cites W2972996513 @default.
• W4313703357 cites W3035468154 @default.
• W4313703357 cites W3081830235 @default.
• W4313703357 cites W3086148163 @default.
• W4313703357 cites W3088173406 @default.
• W4313703357 cites W3092582090 @default.
• W4313703357 cites W3094534128 @default.
• W4313703357 cites W3101633024 @default.
• W4313703357 cites W3118615836 @default.
• W4313703357 cites W3135510359 @default.
• W4313703357 cites W3214317007 @default.
• W4313703357 cites W4206532513 @default.
• W4313703357 cites W4313703357 @default.
• W4313703357 doi "https://doi.org/10.1111/1753-0407.13348" @default.
• W4313703357 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36610036" @default.
• W4313703357 hasPublicationYear "2023" @default.
• W4313703357 type Work @default.
• W4313703357 citedByCount "2" @default.
• W4313703357 countsByYear W43137033572023 @default.
• W4313703357 crossrefType "journal-article" @default.
• W4313703357 hasAuthorship W4313703357A5001830358 @default.
• W4313703357 hasAuthorship W4313703357A5056754675 @default.
• W4313703357 hasAuthorship W4313703357A5082538862 @default.
• W4313703357 hasAuthorship W4313703357A5086188167 @default.
• W4313703357 hasBestOaLocation W43137033571 @default.
• W4313703357 hasConcept C126322002 @default.
• W4313703357 hasConcept C126894567 @default.
• W4313703357 hasConcept C134018914 @default.
• W4313703357 hasConcept C142724271 @default.
• W4313703357 hasConcept C159641895 @default.
• W4313703357 hasConcept C168563851 @default.
• W4313703357 hasConcept C204787440 @default.
• W4313703357 hasConcept C207103383 @default.
• W4313703357 hasConcept C27081682 @default.
• W4313703357 hasConcept C2780306776 @default.
• W4313703357 hasConcept C44249647 @default.
• W4313703357 hasConcept C555293320 @default.
• W4313703357 hasConcept C71924100 @default.
• W4313703357 hasConcept C82789193 @default.
• W4313703357 hasConcept C95190672 @default.
• W4313703357 hasConceptScore W4313703357C126322002 @default.
• W4313703357 hasConceptScore W4313703357C126894567 @default.
• W4313703357 hasConceptScore W4313703357C134018914 @default.
• W4313703357 hasConceptScore W4313703357C142724271 @default.
• W4313703357 hasConceptScore W4313703357C159641895 @default.
• W4313703357 hasConceptScore W4313703357C168563851 @default.
• W4313703357 hasConceptScore W4313703357C204787440 @default.
• W4313703357 hasConceptScore W4313703357C207103383 @default.
• W4313703357 hasConceptScore W4313703357C27081682 @default.
• W4313703357 hasConceptScore W4313703357C2780306776 @default.
• W4313703357 hasConceptScore W4313703357C44249647 @default.
• W4313703357 hasConceptScore W4313703357C555293320 @default.
• W4313703357 hasConceptScore W4313703357C71924100 @default.
• W4313703357 hasConceptScore W4313703357C82789193 @default.
• W4313703357 hasConceptScore W4313703357C95190672 @default.
• W4313703357 hasIssue "1" @default.
• W4313703357 hasLocation W43137033571 @default.
• W4313703357 hasLocation W43137033572 @default.
• W4313703357 hasLocation W43137033573 @default.
• W4313703357 hasOpenAccess W4313703357 @default.
• W4313703357 hasPrimaryLocation W43137033571 @default.
• W4313703357 hasRelatedWork W1544023406 @default.

• next